Stockscreener 앱 받기
31.40
3.05%
-1.01
전일 마감가:
$32.41
열려 있는:
$32.13
하루 거래량:
4.83M
Relative Volume:
0.86
시가총액:
$22.57B
수익:
$13.31M
순이익/손실:
$-1.01B
주가수익비율:
-26.87
EPS:
-1.1685
순현금흐름:
$-766.86M
1주 성능:
+6.51%
1개월 성능:
+7.28%
6개월 성능:
+55.40%
1년 성능:
+188.01%
1일 변동 폭
$30.86
$32.71
1주일 범위
$27.85
$32.79
52주 변동 폭
$10.59
$32.79
Roivant Sciences Ltd Stock (ROIV) Company Profile
명칭
Roivant Sciences Ltd
전화
441-295-5950
주소
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
31.39 | 23.31B | 13.31M | -1.01B | -766.86M | -1.1685 |
VRTX
Vertex Pharmaceuticals Inc
|
432.22 | 109.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
642.17 | 68.12B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
824.26 | 50.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
300.38 | 39.85B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
152.86 | 31.96B | 742.00K | -1.37B | -1.07B | -7.0731 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-20 | 개시 | Bernstein | Outperform |
| 2025-09-02 | 개시 | Citigroup | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-01-05 | 개시 | Piper Sandler | Overweight |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-17 | 개시 | Guggenheim | Buy |
| 2023-06-08 | 개시 | BofA Securities | Neutral |
| 2022-10-27 | 개시 | JP Morgan | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-15 | 개시 | Goldman | Buy |
| 2021-11-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-28 | 개시 | Citigroup | Buy |
| 2021-10-26 | 개시 | Cowen | Outperform |
| 2021-10-26 | 개시 | Jefferies | Buy |
| 2021-10-26 | 개시 | Truist | Buy |
모두보기
Roivant Sciences Ltd 주식(ROIV)의 최신 뉴스
TD Cowen raises Roivant Sciences stock price target to $41 on trial data - Investing.com Australia
Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2025 Earnings Call Transcript - Insider Monkey
Roivant Sciences Ltd. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ROIV) 2026-05-21 - Seeking Alpha
TD Cowen Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $41 - Moomoo
Roivant (ROIV) Climbs 15% on Swing to Profits - Insider Monkey
Roivant Sciences Earnings Call Highlights High-Impact Pipeline - TipRanks
Roivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Long Term Bullish Narratives - simplywall.st
Earnings Call Summary | Roivant Sciences(ROIV.US) Q4 2025 Earnings Conference - 富途牛牛
Roivant anticipates $950M Moderna payment in July as it outlines 2H 2026 mosliciguat and IMVT-1402 readouts - MSN
Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $36.68, Implies 30% Upside - TradingView
Roivant/Immunovant Find Success In Tough-To-Treat RA, Where J&J Failed - Citeline News & Insights
Roivant Sciences Ltd (ROIV) Q4 2025 Earnings Call Highlights: Strategic Settlements and ... By GuruFocus - Investing.com Canada
Roivant Sciences stock hits all-time high of 30.35 USD By Investing.com - Investing.com Nigeria
Roivant Sciences (ROIV) Surges 14.8% to $32.38 - AlphaStreet
Roivant Sciences earnings beat by $0.57, revenue fell short of estimates - Investing.com India
Roivant reports Q4 FY2026 income on Moderna legal settlement - grafa.com
Why is Roivant Sciences stock surging today? By Investing.com - Investing.com South Africa
ROIV: High efficacy in refractory RA, strong cash, and major launches expected in the coming year - TradingView
2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug -- Barrons.com - Moomoo
Roivant Sciences Shares Jump 14.43% to $32.28 on Strong IMVT-1402 Rheumatoid Arthritis Data - International Business Times Australia
Roivant Sciences Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 - marketscreener.com
Sector Update: Healthcare - Moomoo
Roivant gains after mid-stage trial data for Immunovant’s main asset - Seeking Alpha
Roivant Sciences Q4 Earnings Call Highlights - inkl
Immunovant Q4 Earnings Call Highlights - inkl
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Movin - Benzinga
Roivant Sciences stock hits all-time high of 30.35 USD - Investing.com
Roivant Sciences Ltd reports results for the quarter ended March 31Earnings Summary - TradingView
Roivant Sciences Swings to Fiscal Q4 Net Income, Revenue Decreases - Moomoo
Earnings call transcript: Roivant Sciences surprises with Q4 2026 EPS beat - Investing.com Canada
Roivant Sciences Reports Q4 2026 Results: Full Earnings Call Transcript - Benzinga
Roivant Shares Climb on Earnings Beat Despite Revenue Shortfall (ROIV) - Yahoo Finance
Roivant Sciences : Financial Results and Business Updates for the Year Ended March 31 2026 - marketscreener.com
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
ROIV: Strong clinical progress, major litigation win, and robust cash position set up multiple 2027 catalysts - TradingView
Roivant Sciences Ltd. Reports FY2025 Financial Results and Key Developments in May 2026 - Minichart
Roivant shares jump 10% on earnings beat despite revenue miss By Investing.com - Investing.com Australia
Roivant Sciences Ltd. 2026 Annual Report: Business Overview, Risk Factors, and Product Pipeline Highlights - Minichart
Roivant Sciences Q4 2026 Earnings Call Transcript - MarketBeat
Roivant shares jump 10% on earnings beat despite revenue miss - Investing.com
Roivant Sciences Ltd. FY 2026: Revenue $8.26M, EPS ($0.54) — 10-K Summary - TradingView
Roivant Reports $355.7M Q4 Income from Continuing Ops, $4.3B Cash Position - TradingView
Earnings Flash (ROIV) Roivant Posts Fiscal Q4 EPS From Continuing Operations $0.28 - marketscreener.com
Roivant (ROIV) touts late-stage pipeline and Genevant’s $2.25B Moderna IP deal - Stock Titan
Earnings Flash (ROIV) Roivant Sciences Ltd. Reports Q4 Revenue $2.5M, vs. FactSet Est of $3.4M - marketscreener.com
Roivant (NASDAQ: ROIV) books $770M legal gain and holds $4.3B cash - Stock Titan
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update - The Manila Times
Roivant Sciences Ltd. (ROIV) Tops Q4 EPS by 57c - StreetInsider
Earnings Flash (ROIV) Roivant Sciences Ltd. Reports Q4 Revenue $2.5M, Vs. FactSet Est of $3.4M - Moomoo
Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $36.23, Implies 28% Upside - TradingView
How The Roivant Sciences (ROIV) Story Is Shifting After Settlements And Brepocitinib Milestones - Yahoo Finance
Roivant Sciences Ltd (ROIV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Roivant Sciences Ltd 주식 (ROIV) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Venker Eric | President & Immunovant CEO |
Apr 20 '26 |
Sale |
29.59 |
200,000 |
5,918,000 |
1,647,546 |
| Gline Matthew | CEO |
Apr 16 '26 |
Sale |
29.16 |
289,774 |
8,449,810 |
16,736,116 |
0.06%
0.47%
자본화:
|
볼륨(24시간):